Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. - Mackean,M.; Planting,A.; Twelves,C.; Schellens,J.; Allman,D.; Osterwalder,B.; Reigner,B.; Griffin,T.; Kaye,S.; Verweij,J. (J Clin Oncol, 1998)